Compare Moderna, Inc. (MRNA) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oscar Health Inc — how do they compare? Moderna, Inc. trades at $136.38 (market cap $54.14B), while Oscar Health Inc trades at $31.75 (market cap $9.80B). The key difference: Moderna, Inc. is far larger — about 5.5× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | OSCR | |
|---|---|---|
Market Cap | $54.14B | $9.80B |
Sector | Health | Health |
52-Week High | $174.38 | $33.01 |
52-Week Low | $22.36 | $10.85 |
Enterprise Value | $50.29B | $6.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
OSCR trades at $33.01, up 2.36% today and near its 52-week high of $33.10, with a bullish technical trend supported by moving averages. The stock shows strong momentum, with Q1 and Q2 2026 earnings beating estimates, and revenue growth from $11.70B in 2025 to $15.30B in 2026. Analyst sentiment is mixed, with a consensus price target of $30.67 below the current price, but recent news highlights membership growth and cost control improvements.
The outlook for OSCR is cautiously optimistic, driven by robust revenue expansion and profitability improvements, though risks include high valuation multiples and reliance on sustained membership growth. Investors may find opportunity in the company's operational turnaround, but should monitor medical cost trends and competitive pressures in the health insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
